Dadun/></a>
				</td>
				<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Inmunoterapia > DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista >

The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma
Authors: Rodriguez, J. (José)
Conde, E. (Eulogio)
Gutierrez, A. (Antonio)
Lahuerta, J.J. (Juan J.)
Arranz, R. (R.)
Sureda, A. (Anna)
Zuazu, J. (Javier)
Fernandez-de-Sevilla, A. (A.)
Bendandi, M. (Maurizio)
Solano, C. (C.)
Leon, A. (Angel)
Varela, M.R. (María Rosario)
Caballero, M.D. (M.D.)
Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL-TAMO)
Keywords: Peripheral T-cell lymphoma
International prognostic index
β-2-microglobulin
Autologous stem cell transplantation
Issue Date: 2007
Publisher: Ferrata Storti Foundation
Publisher version: http://www.haematologica.org/content/92/8/1067.long
ISSN: 1592-8721
Citation: Rodriguez J, Conde E, Gutierrez A, Lahuerta JJ, Arranz R, Sureda A, et al. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 2007 Aug;92(8):1067-1074.
Abstract
BACKGROUND AND OBJECTIVES: Preliminary data on the use of autologous stem cell transplantation (ASCT) as a salvage therapy for peripheral T-cell lymphoma (PTCL) indicate that the results are similar to those obtained in aggressive B-cell lymphomas. The aim of our study was to analyze outcomes of a large series of patients with PTCL with a prolonged follow-up who received ASCT as salvage therapy. DESIGN AND METHODS: Between 1990 and 2004, 123 patients in this situation were registered in the GELTAMO database. The median age at transplantation was 43.5 years; in 91% of patients the disease was chemosensitive. RESULTS: Seventy-three percent of the patients achieved complete remission, 11% partial remission and the procedure failed in 16%. At a median follow-up of 61 months, the 5-year overall and progression-free survival rates were 45% and 34%, respectively. The presence of more than one factor of the adjusted International Prognostic Index (a-IPI) and a high beta2-microglobulin at transplantation were identified as adverse prognostic factors for both overall and progression-free survival and allowed the population to be stratified into three distinct risk groups. INTERPRETATION AND CONCLUSIONS: Our data show that approximately one third of patients with PTCL in the salvage setting may enjoy prolonged survival following ASCT, provided they are transplanted in a chemosensitive disease state. The a-IPI and beta2-microglobulin level predict the outcome after ASCT in relapsing/refractory PTCL.
Permanent link: http://hdl.handle.net/10171/20025
Appears in Collections:DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista
DA - CUN - Hematología y Hemoterapia - Artículos de revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista

Files in This Item:
File:  Haematologica 2007_92 .pdf
Description: 
Size:  240,23 kB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.